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Abstract
Background: Risk factors associated with L. donovani visceral leishmaniasis (VL; kala azar) relapse are poorly characterized.
Methods: We investigated patient characteristics and drug regimens associated with VL relapse using data from Me ´decins
Sans Frontie `res - Holland (MSF) treatment centres in Southern Sudan. We used MSF operational data to investigate trends in
VL relapse and associated risk factors.
Results: We obtained data for 8,800 primary VL and 621 relapse VL patients treated between 1999 and 2007. Records of previous
treatment for 166 VL relapse patients (26.7%) were compared with 7,924 primary VL patients who had no record of subsequent
relapse. PrimaryVL patients who relapsed hadlarger spleenson admission (Hackettgrade $3 vs0, odds ratio (OR) for relapse=3.62
(95% CI 1.08, 12.12)) and on discharge (Hackett grade $3 vs 0, OR=5.50 (1.84, 16.49)). Age, sex, malnutrition, mobility, and
complications of treatment were not associated with risk of relapse, nor was there any trend over time. Treatment with 17-day
sodium stibogluconate/paromomycin (SSG/PM) combination therapy vs 30-day SSG monotherapy was associated with increased
risk of relapse (OR=2.08 (1.21, 3.58)) but reduced risk of death (OR=0.27 (0.20, 0.37)), although these estimates are likely to be
residually confounded. MSF operational data showed a crude upward trend in the proportion of VL relapse patients (annual
percentage change (APC)=11.4% (23.4%, 28.5%)) and a downward trend in deaths (APC=218.1% (222.5%, 213.4%)).
Conclusions: Splenomegaly and 17-day SSG/PM vs 30-day SSG were associated with increased risk of VL relapse. The crude
upward trend in VL relapses in Southern Sudan may be attributable to improved access to treatment and reduced mortality
due to SSG/PM combination therapy.
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Introduction
Visceral leishmaniasis (VL, kala-azar) is a systemic parasitic
disease caused by the Leishmania donovani species complex. VL
manifests with irregular bouts of fever, substantial weight loss,
hepatosplenomegaly, pancytopenia, and susceptibility to opportu-
nistic infection [1]. VL is typically fatal unless treated. In
immunocompetent individuals, effective drug treatment reduces
Leishmania amastigotes to a level undetectable in aspirates. An
effective life-long cellular immune response normally develops,
and residual parasites are suppressed [2]. Despite apparent clinical
and parasitologic response to treatment, a proportion of VL
patients who are apparently otherwise immunocompetent, have a
recurrence of VL. This usually occurs within 6 months of
treatment [1,3], and later recurrence is rare – suggesting that
recrudescence rather than re-infection is the usual mechanism of
relapse. While the role of HIV infection in VL relapse is well-
documented, for example among patients in southern Europe, risk
factors for VL relapse among HIV-negative patients in VL-
endemic regions of Africa remain poorly characterised.
Me ´decins Sans Frontie `res - Holland (MSF) has treated
.80,000 VL patients in Sudan and Ethiopia since 1989, and
has maintained an electronic record of patient characteristics,
treatments and outcomes. Although these routinely-collected data
are intrinsically incomplete due to the very challenging
environment in which they are collected, our previous analyses
have yielded important findings [3–10]. Most recently, we
analysed risk factors for VL relapse in patients in Northern
Ethiopia who were co-infected with HIV [11]. In contrast, the
prevalence of HIV in Southern Sudan has remained the lowest in
Africa until very recently [12]. Here we investigate risk factors for
VL relapse among patients from this largely HIV-negative
population who were treated at MSF clinics in Southern Sudan
from 1999 to 2007.
Methods
Diagnosis
Diagnostic, treatment, and discharge procedures used were
consistent with WHO guidelines [13]. VL was diagnosed in
www.plosntds.org 1 June 2010 | Volume 4 | Issue 6 | e705clinical suspects by high titer ($1:6,400) antibodies to Leishmania
(freeze-dried Leishmania antigen supplied by the Royal Tropical
Institute, Amsterdam, The Netherlands) in a direct agglutination
test (DAT); or by microscopy of splenic or lymph node aspirates;
or (since 2004) by rK39 rapid diagnostic test (DiaMed-IT-Leish
supplied by DiaMed AG, Cressier sur Morat, Switzerland); or on
rare occasions when laboratories were not functioning, by clinical
judgment (criteria: fever .2 weeks with exclusion of malaria and
either splenomegaly or lymphadenopathy and wasting).
Treatment
Until 2002, standard treatment for primary VL comprised
daily IM injections of sodium stibogluconate (SSG; Albert David
Ltd, Calcutta; supplied by the International Dispensary
Association, Amsterdam, The Netherlands) at a dose of 20mg/
kg/day (minimum dose, 200mg; no maximum dose) for 30 days.
Between 2001 and 2003, SSG monotherapy as standard
treatment was replaced with combination therapy of paromo-
mycin (PM) plus SSG. This comprised 17 daily intramuscular
injections of SSG 20mg/kg and paromomycin sulfate (Phar-
mamed Parenterals Ltd, Malta, supplied by the International
Dispensary Association, Amsterdam, The Netherlands) at a dose
of 15mg/kg (equivalent to ,11mg/kg of PM base). SSG/PM
was initially withheld from females of childbearing age, and
since 2004 withheld only from pregnant women. SSG/PM was
administered only at MSF treatment centres with a permanent
expatriate doctor, and these centres also had access to parenteral
antibiotics and therapeutic feeding. In 2003 MSF introduced a
formal risk assessment using a scoring system based on known
risk factors for adverse outcomes [3]. Thereafter, critically ill
patients at high risk of death were treated initially in special care
areas with rehydration, therapeutic nutrition, antibiotics, and
liposomal amphotericin B (AmBisomeH, Gilead Pharmaceuti-
cals); when their condition improved, treatment continued with
SSG/PM. Before the introduction of this ‘‘combined AmBi-
some-paromomycin-stibogluconate treatment’’ (CAPST) in
2003, treatment with AmBisome was unusual. The prohibitive
cost of AmBisome was reduced for public sector agencies in
developing countries in 2007, allowing all critically ill patients to
be treated with a full course of AmBisome.
Discharge
Cases of primary VL who did not respond clinically to
treatment underwent a test-of-cure aspirate from spleen or lymph
node. If the test-of-cure result was positive, daily SSG injections
were continued until two consecutive weekly test-of-cure results
were negative. Patients whose aspirate remained positive after
$60 SSG injections were treated with combinations of SSG, PM
and AmBisome. On discharge, patients were given an identifica-
tion card to be presented in case of re-admission for relapse or for
post kala-azar dermal leishmaniasis (PKDL).
Re-admission
Patients with possible relapse of VL (i.e. patients who presented
their identification card from previous treatment or who verbally
reported previous treatment) were diagnosed by splenic or lymph
node aspirate. Relapsed VL patients were treated with 17 days of
SSG/PM plus further daily injections of SSG until two weekly test-
of-cure results were negative. Patients who relapsed $2 times were
treated with 6 IV doses of 4–6mg/kg of AmBisome on alternate
days. In patients with relapses, tuberculosis (TB) and HIV were
considered as possible co-factors and appropriate tests done. In
rare cases of repeated VL relapses, empiric TB treatment was
sometimes given. Patients with severe PKDL were treated with
SSG or, if not responding, a combination of SSG/PM, until their
condition improved.
Data sources
Since 1999 we have made an electronic archive of VL patient
records from MSF treatment centres in Southern Sudan.
Demographic, diagnostic, treatment, and discharge data were
handwritten on a card during a patient’s stay at a treatment
centre. MSF staff at our Lokichoggio base on the Sudan/Kenya
border entered data from these cards into EpiInfo, version 6
(Centres for Disease Control and Prevention). Due to time and
resource constraints, all data were single-entered. During the
period 1999–2007, MSF treatment centres were situated in Upper
Nile State (Abuong, Atar, Bimbim, Magang, Rupbuot, Wudier),
Jonglei State (Lankien, Pieri, Pading), and Unity State (Bil, Leer,
Nimne, Thonyor). For analysis of trends we used MSF operational
data, which provided monthly summary statistics on total VL
treatment activity (admissions, diagnoses and outcomes) at each
treatment centre.
Data cleaning
Anomalous, inconsistent, or missing values were identified and
corrected if possible, otherwise recoded as missing. Adult (age .19
years) body mass index (BMI) values were re-calculated from
weight and height data. Weight-for-height (WFH) Z-scores for
children age ,5 years were generated using WHO Anthro 2005
software (World Health Organisation, Geneva). BMI-for-age Z-
scores for patients 5–19 years old were calculated using WHO
Survey 2007 software (World Health Organisation, Geneva) [14].
Inclusion criteria
This study was concerned only with patients with primary VL
(i.e. no record of previous treatment) during 1999–2007. In the
first year (1999), Lankien was the only functioning VL treatment
centre in the area, with only 443 primary VL admissions and a
recorded relapse rate of 3.7% by passive case-finding; we consider
it unlikely that any of these primary VL patients were
misdiagnosed VL relapse patients who had been treated elsewhere,
because VL treatment had not been available elsewhere in the
region. Patients who subsequently relapsed were identified by
Author Summary
Visceral leishmaniasis (kala-azar) caused by Leishmania
donovani is spread from person to person by Phlebotomus
sandflies. Major epidemics of visceral leishmaniasis have
occurred in Southern Sudan during the 20th century. The
worst of these killed 100,000 people in the western Upper
Nile area of Southern Sudan from 1984–1994, a loss of one-
third of the population. Me ´decins Sans Frontie `res has
treated 40,000 kala-azar patients in Southern Sudan since
the late 1980’s. In this study we used routinely collected
clinical data to investigate why some patients relapse after
treatment. We found that patients with severely enlarged
spleens (splenomegaly) are more likely to relapse. Patients
treated for 17 days with a combination of two drugs
(sodium stibogluconate and paromomycin) were more
likely to relapse (but less likely to die) than patients treated
for 30 days with a single drug (sodium stibogluconate).
However, the transition from sodium stibogluconate to the
sodium stibogluconate/paromomycin combination as
standard treatment between 2001–2003 has not led to a
significant increase in visceral leishmaniasis relapse.
Visceral Leishmaniasis Relapse in Southern Sudan
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their patient identifier, sex and age. Patients who died or defaulted
(self-discharge against medical advice) during treatment were
excluded from our analysis of risk factors for relapse.
Outcomes
Our primary outcome was relapse after treatment for primary
VL. We also analysed death during VL treatment as a secondary
outcome in a comparison of SSG/PM vs SSG.
Variables
We used the following admission data: age, sex, treatment
centre, calendar year, self-reported duration of illness (‘time-to-
presentation’), walking status for patients $5 years old (walking
normally, with a stick, or with assistance or carried on stretcher - a
marker for general weakness). Data on admission and discharge
included: body mass index (BMI) (for patients .19 years old),
BMI-for-age Z-score (for patients 6–19 years old) [14], weight-for-
height (WFH) Z-score (for patients #5 years old), spleen size
(Hackett grade) [15], and haemoglobin (g/dl) (measured by color
densitometry before 2006; Haemocue thereafter). Malnutrition in
appropriate age groups was defined as: BMI,14kg/m
2; BMI-for-
age Z-score,23; and WFH Z-score,23. Treatment data
included: drug used and occurrence of diarrhoea, bleeding and
vomiting. The majority of patients were treated at one centre
(Lankien) which differed from the other (smaller) treatment centres
in that expatriate and/or experienced national medical staff were
stationed there permanently (except when evacuated for reasons of
security). Hence, treatment centre was coded dichotomously to
indicate Lankien or ‘other’ treatment centre.
Statistical analysis
We compared patients and outcomes by Chi-squared test and t-
test. Odds ratios for VL relapse, adjusted a-priori for age, sex,
treatment centre, and time (calendar year), were estimated for all
variables; those variables which were associated with VL relapse
were then included, with the a-priori confounders, in a
multivariable logistic regression model. All statistical analyses
were performed using Stata Release 10 (StataCorp. 2007. Stata
Statistical Software: Release 10. College Station, TX). Trends based
on MSF operational data (summary statistics) were analysed using
US National Cancer Institute Join-point regression software,
version 3.0 (http://srab.cancer.gov/joinpoint/), which performs
linear regression to estimate the annual percent change (APC) in
the dependent variable (rates are assumed to change at a constant
percentage of the rate of the previous year, ie. to change linearly
on a log scale) and the number and location of join-points (points
at which trends change) [16]. The software performs pair-wise
comparisons of models differing by one join-point to determine the
model with the optimum fit to the data series. An overall
significance level of 5% was adopted for the comparisons of
models applied to each data series. We tested different
permutations of the maximum number of join-points (2, 3 or 4),
the minimum number of observations between joinpoints (3 or 4)
and the minimum number of observations between joinpoints and
the ends of the data (2 or 3).
Sensitivity analyses
(1) Patients without an enlarged spleen could not undergo spleen
aspirate, and lymph node aspirates were performed by MSF at
only one centre (Lankien), hence we suspected that some VL
patients diagnosed by DAT alone may have been misdiagnosed,
because DAT has a false positive rate of $10% [17,18]. We
therefore performed a sensitivity analyses, excluding patients
without splenomegaly on admission, to assess the degree of mis-
diagnosis. (2) The transition from SSG to SSG/PM in the second
half of the period in our study was accompanied by an increase in
the proportion of VL relapse patients for whom a record of
previous treatment could be identified. In order to assess possible
bias in estimating the association of SSG/PM vs SSG with risk of
relapse, we performed a sensitivity analysis in which we assumed
that VL relapse patients for whom a record of previous treatment
could not be identified (hence, who were excluded from the main
analysis of risk factors for relapse) had the same characteristics on
admission for primary VL (same age, sex, treatment centre, time of
treatment and treatment with SSG or SSG/PM) as they did on
admission for relapse VL.
Ethics approval
Data were collected as part of routine patient care; no
additional investigations were performed. Ethical approval was
obtained from the MSF Ethical Review Board.
Results
Characteristics of patients
The treatments for which electronic archive data were available
are summarised in Table 1. Overall, records were available for
78.2% (10,105/12,924) of treatments, according to MSF monthly
field activity reports. For relapse VL, the corresponding propor-
tion of treatments with entered data was higher, at 88.1% (621/
705) (Figure 1). The Lankien and Pieri treatment centres were
looted in 2004 and 2006, respectively, with the loss or destruction
of many treatment cards. Other losses of treatment cards were due
to generally adverse conditions in the field and difficulties in
collecting and transporting paper records from remote sites, some
of which had no permanent expatriate presence.
Our analysis was based on primary VL patients who were
known to have subsequently relapsed because a record of
treatment for VL relapse could be linked with their primary VL
treatment record (Figure 1). These relapse patients (N=166)
were a subset (26.7%) of all VL relapse patients who had an
electronic record of treatment for relapse VL (N=621). Table 2
shows a comparison of the characteristics of VL relapse patients
who did or did not have a record of previous treatment for
primary VL. Patients for whom we could not identify a previous
treatment record had more missing data, higher adult BMI, longer
duration of illness, and less splenomegaly than patients whose
previous treatment data were used in our analysis of factors
associated with VL relapse, but there were no differences in age,
sex, nutritional status of patients #19 years old, haemoglobin,
walking status, drug treatment, or treatment outcome. More than
half (57.8%) of the 621 VL relapse patients were treated at one
centre (Lankien), and a record of previous treatment was available
for 34.3% (123/359) of these patients compared with 16.4% (43/
262) for all other treatment centres combined (P,0.001). A record
of previous treatment was more likely to be identified in the second
half of the period under study (36.5% in 2003–2007) compared
with the first half (14.1% in 1999–2002) (P,0.001).
Factors associated with VL relapse among patients
treated for primary VL
Table 3 shows a comparison of the characteristics on admission
of primary VL patients who did or did not have a recorded
subsequent relapse. Higher odds of relapse were associated with
splenomegaly (on admission for, and discharge from, treatment for
primary VL) and with SSG/PM treatment of primary VL. In a
Visceral Leishmaniasis Relapse in Southern Sudan
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treatment centre, admission spleen size (Hackett grade) $3 was
associated with .4-fold higher odds of relapse compared with size
0 (odds ratio (OR)=4.40 (95% CI 1.74–11.08), P=0.002).
Admission spleen grades 1 and 2 were associated with .2-fold
and 3-fold higher odds: OR=2.43 (0.95–6.26), P=0.02 for size 1
vs size 0; OR=2.91 (1.17–7.24), P=0.07 for size 2 vs size 0. In a
similarly-adjusted model, 17-day SSG/PM was associated with
.2-fold higher odds of relapse (OR=2.26 (1.46–3.51), P,0.001)
compared with 30-day SSG monotherapy. This estimate was
robust to a sensitivity analysis in which the N=455 VL relapse
patients for whom no record of previous treatment was available
were included in the dataset as primary VL patients who
subsequently relapsed, under the assumption that these patients
were treated with the same drug for both VL episodes (OR=2.25
(1.79–2.82), P,0.001).
Young age (,5 years) was not associated with risk of relapse.
However, among children ,5 years old, infancy (age ,1 year)
compared with age 1–4 years was associated with higher risk of
relapse (OR=3.47 (1.16–10.37), P=0.03). Patients treated at
Lankien were more than twice as likely to relapse (OR=2.32
(1.61–3.36), P,0.001) as patients treated at any other centre
(model adjusted for age, sex and year of treatment).
Test-of-cure data were available for only 4.2% (7/166) of
relapse patients who had a previous treatment record vs 5.4%
(431/7,924) of patients with no record of subsequent relapse
(P=0.6). None of the final test-of-cure results for relapse patients,
and only 3/431 of the test-of-cure results for patients with no
record of subsequent relapse were positive. Hence, test-of-cure
data were not included in the risk factor analysis. Whether or not a
test-of-cure was performed (indicative of non-response to treat-
ment) was not associated with risk of relapse (OR=1.19, 95% CI
0.60–2.34).
Patients who did not have a recorded relapse were missing more
height and weight data, but none of the anthropometric measures
on admission were associated with VL relapse. Although mean
hemoglobin was not associated with VL relapse, in multivariable
regression (adjusted for age, sex, year and treatment centre)
primary VL patients presenting with hemoglobin in the lowest
quartile (#7.0g/dl) had an odds ratio for relapse of 2.60 (1.00–
6.74), P=0.05) compared with patients in the highest quartile
(.10g/dl). Splenomegaly and anemia were strongly correlated
(decrease in Hb concentration for each increment in Hackett
grade=0.47 (0.40–0.54) g/dl, P,0.001, by linear regression
adjusted for age and sex).
Higher risk of relapse was also strongly associated with spleen
size at end of treatment (OR=5.41 (1.89–15.47), P=0.002 for size
$3 vs size 0; OR=2.09 (1.19–3.67), P=0.01 for size 2 vs size 0;
OR=1.45 (0.82–2.53), P=0.2 for size 1 vs size 0) (Table 4).
These associations were slightly attenuated if we excluded patients
who had no palpable spleen or no spleen size data on admission
(OR=5.01 (1.75–14.37), P=0.003 for size $3 vs size 0;
OR=1.98 (1.12–3.48), P=0.02 for size 2 vs size 0; OR=1.31
(0.74–2.34), P=0.4 for size 1 vs size 0). Spleen size at end of
treatment for primary VL was not correlated with spleen size on
admission for relapse VL (pairwise correlation coefficient=0.12,
P=0.2).
There were gains in BMI and WFH during treatment among
patients who did and who did not have a subsequently recorded
relapse, although these gains were statistically evident (P,0.001)
only for the (much larger) group of non-relapsing patients. Weight
on discharge was recorded for only 50% of patients. Among
patients of all ages, the mean gain in body weight (as a percentage
of weight on admission) was higher in non-relapsing patients
(4.2%) than in relapsing patients (2.4%). In a linear regression
model (adjusted for age, sex, year, treatment centre, and weight on
admission), the difference in percentage weight gain between non-
relapsing and relapsing patients was 2.29% (95% CI 0.43%–
4.14%; P=0.02).
In a multivariable model (Table 5) comprising age, sex, year,
treatment centre, spleen size on admission, spleen size on
discharge, and treatment given (SSG/PM vs SSG): splenomegaly
Hackett grade $3 on admission for, and on discharge from,
treatment for primary VL were independently associated with
higher odds of subsequent relapse compared with size 0 (on
admission OR=3.62 (1.08–12.12), P=0.04; on discharge
OR=5.50 (1.84–16.49), P=0.002); SSG/PM was associated with
higher odds of relapse (OR=2.08 (1.21–3.58), P=0.008); and
Table 1. Primary VL, relapse VL and PKDL treatment data from Me ´decins Sans Frontie `res - Holland clinics in Southern Sudan
(1999–2007).
1999 2000 2001 2002 2003 2004 2005 2006 2007 Total
Primary VL 636 346 1,514 1,766 2,620 1,057 456 354 51 8,800
(86.0%) (77.1%) (89.4%) (86.2%) (90.8%) (84.6%) (88.2%) (77.5%) (78.5%) (87.1%)
Relapse VL 31 54 53 132 165 79 25 72 10 621
(4.2%) (12.0%) (3.2%) (6.4%) (5.8%) (6.3%) (4.8%) (15.8%) (15.4%) (6.1%)
PKDL 73 49 126 151 101 113 36 31 4 684
(9.9%) (10.9%) (7.5%) (7.4%) (3.5%) (9.0%) (7.0%) (6.8%) (6.1%) (6.8%)
Total for whom treatment
data were entered
740 449 1,693 2,049 2,886 1,249 517 457 65 10,105
(100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%) (100.0%)
Total number of treatments
a 799 540 1,909 2,111 3,414 1,934 1,447 590 180 12,924
Proportion for whom data were entered 92.6% 83.1% 88.7% 97.1% 84.5% 64.6% 35.7% 77.5% 36.1% 78.2%
Proportion of primary VL
patients treated in Lankien
b
58.4% 45.4% 41.2% 80.9% 80.4% 4.8% 75.0% 76.8% 98.0% 61.4%
afrom MSF summary statistics.
blow proportion in 2004 due to looting of Lankien and consequent loss of patient medical record.
doi:10.1371/journal.pntd.0000705.t001
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(1.14–2.72), P=0.01) than patients treated at any other centre. In
a sensitivity analysis, excluding patients who had spleen size 0 or
missing spleen size data on admission from this model (Table 5),
the association of splenomegaly on discharge with higher odds of
relapse was slightly attenuated (OR=5.38 (1.79–16.12), P=0.003
for size $3 vs size 0), as was the association of SSG/PM with
higher odds of relapse (OR=2.02 (1.16–3.51), P=0.01). SSG/PM
compared with SSG monotherapy was associated with 73% lower
odds of death among primary VL patients (OR=0.27 (0.20–0.37),
P,0.001) and 85% lower odds of death among relapse VL
patients (OR=0.15 (0.05–0.46), P=0.001), in models adjusted for
age, sex, year and treatment centre.
Trends in VL relapse and related factors in Southern
Sudan
Table 6 shows summary statistics for the proportion of patients
admitted to MSF treatment centres in Southern Sudan who were
diagnosed with VL relapse (expressed as a proportion of patients
treated for primary VL). Join-point analysis provided weak
evidence (P=0.12) for an upward trend in this proportion (annual
percent change (APC)=11.4% (23.4% to 28.5%)), as illustrated
in Figure 2. The proportion of patients who died fell dramatically
between 1999 and 2001 (from 13.5% to 7.4%) and then declined
steadily to ,3% in 2006/2007. Join-point analysis provided strong
evidence (P,0.001) for a downward trend in deaths during
treatment for VL over the period 1999–2007 (APC=218.1%
(222.5% to 213.4%), P,0.001) (Table 6, Figure 2). These
trends in relapse and deaths were corroborated by logistic
regression models (including age, sex, and treatment centre),
which showed no discernible trend in risk of relapse (OR=1.04
(0.95–1.14), P=0.4), but a clear decline in risk of death
(OR=0.81 (0.77–0.86) per year, P,0.001).
The proportion of primary VL patients presenting with
splenomegaly indicated by Hackett Grade $3 decreased from
34.4% in 1999 to 16.0% in 2007 (Table 6, Figure 2); a trend of
Figure 1. Patients treated by MSF in Southern Sudan (1999–2007) who were included in this study.
doi:10.1371/journal.pntd.0000705.g001
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time-to-presentation for primary VL patients fell from 2.8 to 1.2
months, and for relapse patients from 3.0 months in 1999 to 1.6
months in 2007 (Table 6). Join-point analysis showed a steady
downward trend in the mean time-to-presentation of VL relapse
patients (APC=26.7% (211.3% to 21.8%), P=0.003) and of
primary VL patients (APC=27.7% (23.8% to 211.6%),
P=0.003) (Table 6, Figure 2). Figure 2 also shows that the
proportion of primary VL patients treated with SSG/PM
combination therapy, instead of SSG monotherapy, increased
from ,1% in 2001 to 90% in 2003 (Table 6). We found no trends
in age and sex or in nutritional and walking status.
The median interval between discharge from treatment for
primary VL and re-admission for VL relapse was 91 days (range
19–1358 days, N=166) (Table 6); the median interval in years
1999–2003 (105 days) was longer (by 27 days) than in years 2004–
2007 (Kruskal-Wallis test, 1df, P=0.04). The overall proportion of
patients relapsing within 3 months was 49.4%; within 6 months
83.7%; and within 12 months 96.4%. The interval between
discharge from treatment for primary VL and re-admission for
relapse was not associated with age, sex, spleen size on discharge,
nutritional status on discharge or drug regimen.
Discussion
We have shown that splenomegaly among patients with primary
L. donovani VL was strongly associated with a much higher relative
risk of VL relapse. Primary VL patients presenting with
splenomegaly of Hackett Grade $3 had almost four-fold higher
odds of subsequent relapse than patients with no enlargement of
the spleen, and patients discharged with greatly enlarged spleens
had greater than five-fold higher odds of relapse. The latter, but
not the former, association remained evident after excluding from
our analysis all patients who had no palpable spleen on admission
Table 2. Characteristics of relapse VL patients (N=621) who did or did not have a record of previous treatment for primary VL.
Relapse VL patients who
had a record of treatment
for primary VL (N=166)
Relapse VL patients who
did not have a record of
treatment for primary VL (N=455) P-value*
Age group ,5 years 18.7% 20.9% 0.8
5–19 years 47.6% 46.4%
.19 years 33.7% 32.8%
Sex Male 59.6% 57.1% 0.6
Treatment centre Lankien 74.1% 51.9% ,0.001
Other 25.9% 48.1%
Mean BMI (patients .19 years) (kg/m
2) (n=51) 15.24 (n=108) 16.14 0.01
Mean BMI-for-age Z-score (patients 5–19 years) (n=65) 23.34 (n=149) 23.05 0.3
Mean WFH Z-score (patients ,5 years) (n=31) 22.21 (n=86) 22.53 0.4
Malnourished (Z-score,23 or BMI,14kg/m
2) 41.6% 34.9% 0.2
Missing height or weight data 11.5% 24.6% ,0.001
Mean hemoglobin (g/dl) 8.32 8.27 0.9
Missing hemoglobin data 54.2% 73.9% ,0.001
Mean duration of illness (months) 1.8 2.5 ,0.001
Missing duration of illness data 5.4% 5.1% 0.9
Spleen size (Hackett Grade) 0 9.6% 11.2% 0.003
1 7.2% 19.1%
2 35.5% 34.7%
$3 42.2% 30.6%
Missing 5.4% 4.4%
Walking status Unassisted 31.9% 34.5% 1.0
With a stick 40.4% 38.7%
Assisted/Stretcher 10.2% 9.9%
Missing 17.5% 16.9%
Drug used for VL relapse SSG 19.3% 28.6% 0.1
SSG/PM 72.3% 65.5%
Other/CAPST 7.2% 5.1%
Missing 0.9% 1.2%
Treatment outcome Discharged 88.6% 87.7% 0.7
Died 6.0% 5.3%
Defaulted 5.4% 7.0%
*Student’s t-test for difference between mean values, Chi-squared test for differences in proportions.
doi:10.1371/journal.pntd.0000705.t002
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emerged as strong risk factors for VL relapse, although infants
appeared to be more susceptible as reported for L. chagasi VL [19].
Splenomegaly on admission may indicate a combination of
severity of illness, parasite burden, and severity of immunosup-
pression. Splenomegaly on discharge suggests the patient has not
responded adequately to treatment, and may either harbour a
significant parasite burden or may still be immunosuppressed by
the disease. Splenomegaly is one of the classical signs of VL,
reported globally as present in .90% of VL patients [13].
Extremely enlarged spleen on admission is a sign of advanced
disease and is a risk factor for death [3]. The spleen in L. donovani
infection is infiltrated by parasitized macrophages as well as
plasma cells, immune complexes and other components of
immune response, leading to hyperplasia of reticulo-endothelial
cells and enlargement of the organ [20]. A chronic inflammatory
state mediated mainly by TNF results in architectural damage and
immunological dysfunction [21,22]. Particularly important for
treatment outcome is loss of spleen marginal zone macrophages,
which play an important role in capturing blood-borne pathogens;
during enlargement, the spleen’s protective role is reduced [23,24].
Through clinical and pathophysiological observation, reduction of
spleen size is recognised as one of the most important signs of
successful treatment, and splenectomy has traditionally been
practiced in splenomegalic patients who have frequent relapses
despite appropriate treatment [25]. However, according to the
WHO Manual on Visceral Leishmaniasis, a completely unpalp-
able spleen is not considered necessary to classify a patient as
cured, (‘‘persistently enlarged spleen is no cause for concern
provided the patient’s other symptoms are improving’’) [13].
Severe anaemia is associated with the increased risk of death
among VL patients [3] and, apart from other reasons (bone
marrow suppression, malnutrition and generalised inflammation),
is related to intensive destruction of erythrocytes in enlarged
Table 3. Characteristics on admission of primary VL patients who did or did not have record of subsequent relapse.
Primary VL patients who
subsequently relapsed
(N=166)
Primary VL patients who had no
record of subsequent relapse
(N=7,924) P-value*
Age group ,5 years 21.1% 17.7% 0.5
5–19 years 45.8% 46.3%
.19 years 33.1% 36.0%
Sex Male 58.4% 52.9% 0.2
Treatment centre Lankien 77.7% 60.4% ,0.001
Other 22.3% 39.6%
Mean BMI (patients .19 years) (kg/m
2) (n=54) 15.50 (n=2,525) 15.57 0.8
Mean BMI-for-age Z-score (patients 5–19 years) (n=65) 23.48 (n=2,882) 23.40 0.6
Mean WFH Z-score (patients ,5 years) (n=30) 22.65 (n=1,254) 22.68 0.9
Malnourished (Z-score,23 or BMI,14kg/m
2) 26.8% 28.6% 0.6
Missing height or weight data 10.2% 15.9% 0.01
Mean admission hemoglobin (g/dl) 8.26 8.66 0.1
Missing hemoglobin data 67.5% 68.4% 0.8
Mean duration of illness (months) 1.73 1.88 0.2
Missing duration of illness data 1.8% 3.1% 0.4
Admission spleen size (Hackett Grade) 0 3.0% 8.1% 0.002
1 20.5% 25.0%
2 44.0% 42.8%
$3 31.3% 20.8%
Missing 1.2% 3.4%
Walking status Unassisted 22.9% 23.1% 1.0
With a stick 48.2% 49.2%
Assisted/Stretcher 15.7% 14.8%
Missing 13.3% 13.0%
Drug used for primary VL SSG 27.1% 43.9% ,0.001
SSG/PM 70.5% 54.8%
Other/CAPST 0.0% 0.5%
Missing 2.4% 0.8%
Vomiting during treatment 28.3% 28.2% 1.0
Bleeding during treatment 2.4% 3.8% 0.4
Diarrhoea during treatment 34.3% 35.2% 0.8
*Student’s t-test for difference between mean values, Chi-squared test for differences in proportions.
doi:10.1371/journal.pntd.0000705.t003
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and anaemia found in our data would be expected. However,
other indicators of advanced disease on admission, such as severe
malnutrition and general weakness expressed as walking status,
were not associated with relapse in our patients. Weight gain is a
sign of clinical response to treatment, and mean percentage weight
gain was marginally lower in the group of patients who
experienced relapse. However, we note that discharge weight
data were missing for 50% of patients. The mean percentage gain
in haemoglobin level was the same in both groups, although data
were missing for 80% of patients. Other signs of clinical response,
such as improvement of general status and becoming afebrile,
were not recorded in our database.
We found that 17-day SSG/PM combination therapy was
associated with two-fold higher odds of relapse than 30-day SSG
monotherapy. The joinpoint analysis showed an upward trend in
VL relapse admissions as a proportion of primary VL admissions
(Figure 2), which might be interpreted as a consequence of the
introduction of SSG/PM as first-line treatment for primary VL
between 2001 and 2003. However, this apparent trend was driven
by the relatively high proportion of VL relapse patients treated in
the last two years (2006–2007), and the risk factor analyses showed
Table 4. Characteristics on discharge of primary VL patients who did or did not have record of subsequent relapse.
Primary VL patients who
subsequently relapsed
(N=166)
Primary VL patients who had no
record of subsequent relapse
(N=7,924) P-value*
Mean BMI (patients .19 years) (kg/m
2) (n=30) 15.88 (n=1,465) 16.14 0.8
Mean BMI gain(+)/loss (2) during treatment (kg/m
2) +0.43 (P=0.2) +0.33 (P,0.001)
Mean BMI-for-age Z-score (patients 5–19 years) (n=33) 22.93 (n=1,769) 22.96 0.9
Mean BMI-for-age Z-score gain(+)/loss (2) during treatment +0.36 (P=0.01) +0.49 (P,0.001)
Mean WFH Z-score (patients ,5 years) (n=17) 22.03 (n=725) 22.17 0.7
Mean WFH Z-score gain(+)/loss (2) during treatment +0.83 (P=0.1) +0.57 (P,0.001)
Malnourished (Z-score,23 or BMI,14kg/m
2) 42.0% 42.0% 1.0
Mean percentage gain in body weight (%) - all ages 2.6% 4.3% 0.07
Missing body weight gain data 51.8% 50.0% 0.05
Mean percentage gain in hemoglobin (%) 18.0% 18.2% 1.0
Missing hemoglobin gain data 79.8% 77.5% 0.5
Discharge spleen size (Hackett Grade) 0 49.4% 58.3% 0.005
1 9.0% 8.0%
2 9.0% 5.6%
$3 2.4% 0.6%
Missing 30.1% 27.4%
*Student’s t-test for difference between mean values, Chi-squared test for differences in proportions.
doi:10.1371/journal.pntd.0000705.t004
Table 5. Multivariable model of risk factors for relapse after treatment for primary VL.
Odds ratio* Odds ratio in sensitivity analysis**
(95% CI) (95% CI)
Admission spleen size (Hackett Grade) 0 1.00 -
1 3.48 (1.05–11.53) 1.00
2 3.27 (1.01–10.55) 0.95 (0.54–1.66)
$3 3.62 (1.08–12.12) 1.05 (0.60–1.84)
Test-for-trend*** P=0.1 P=0.9
Discharge spleen size (Hackett Grade) 0 1.00 1.00
1 1.47 (0.83–2.60) 1.37 (0.76–2.47)
2 1.88 (1.02–3.49) 1.88 (1.02–3.48)
$3 5.50 (1.84–16.49) 5.38 (1.79–16.12)
Test-for-trend*** P=0.003 P=0.002
Use of SSG/PM vs SSG for primary VL 2.08 (1.21–3.58) 2.02 (1.16–3.51)
*adjusted for age, sex, year, treatment centre and all variables in table.
**excluding patients who had spleen size ‘0’ on admission (adjusted for age, sex and all variables in table).
***Wald test-for-trend across spleen size as linear variable.
doi:10.1371/journal.pntd.0000705.t005
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introduced on the basis of evidence from several trials [26–28],
and in a retrospective study (2002–2005) based on MSF treatment
data from Southern Sudan, the SSG/PM regimen was found to
give better survival and cure rates than SSG alone [9]. Preliminary
analysis of a phase III clinical trial by the Drugs for Neglected
Diseases Initiative (DNDi) indicated as yet no difference in cure
rates between 17 days of SSG/PM and 30 days of SSG [DNDi -
unpublished data]; final results of the trial are due in 2010 [29]. It
could be that the very patients who were saved from dying by
SSG/PM may be those who relapsed. This phenomenon probably
occurred during our study of miltefosine vs SSG in Ethiopia:
miltefosine, being a safer drug than SSG, was associated with a far
lower death rate, yet a far higher relapse rate [30]. However, not
all previously-reported risk factors for death were evident as risk
factors for relapse (possibly because drug toxicity is a primary
cause of death) [3], and we cannot discount a possible role of
shorter duration of treatment in increasing risk of relapse [31].
Our reported association between SSG/PM and risk of VL
relapse was likely to be residually confounded, and possibly biased
by missing data, because SSG/PM was used at permanent MSF
treatment centres, whereas SSG monotherapy was used at
temporary (seasonal) outreach sites. Access to care in the event
of VL relapse was much easier at the permanent sites, some of
which have even benefited from public transport since 2005.
Temporary sites were also less able to diagnose relapses, because
the splenic or lymph node aspirates which are necessary to make
the diagnosis of relapse could only be carried out at the main
treatment centres. These factors, together with better record-
keeping, probably explain the apparently higher risk of relapse
associated with treatment at Lankien.
The use of SSG/PM during the latter half of the period in our study
coincided with a series of political agreements (between 2003 and
2005), which brought a tentative ceasefire to Southern Sudan after
decades of conflict. Hence, the crude upward trend seen in MSF’s
summary data is probably a consequence of easier access to treatment,
as reflected in the trend towards shorter ‘time-to-presentation’ for VL
patients (Figure 2). In the past, when access to care was restricted,
patients with relapse may have died without reaching a treatment
centre. HIV infection was unlikely to be a factor in VL relapse during
most of the period in our study. An unlinked screening study of 206
VL patients in Lankien in 2002 revealed only 1 HIV-positive case
(0.5%); or 1 in 36 adult patients (2.8%) [MSF - unpublished data].
However, the number of VL patients has declined in recent years
(from 4,172 in 2003 to 101 in 2008), while large numbers of refugees
have begun to return to Southern Sudan from places with higher HIV
prevalence (Ethiopia, Kenya, Khartoum). Hence we might expect the
proportion of VL relapses attributable to HIV co-infection to increase.
Recent (2008) data from Nasir, where MSF began routine HIV testing
and anti-retroviral therapy in adult VL patients, showed that 25% (5/
20) were HIV co-infected [MSF - unpublished data].
Our study was the largest retrospective analysis of VL relapse
globally. The difficult conditions under which the data were
collected gave rise to some limitations, principally missing
treatment records, missing data and, for this study, our inability
to link all VL relapse patients with their record of treatment for
primary VL. This was mainly because the majority of patients did
not present the identification card given to them when they were
discharged from treatment for primary VL. It is difficult to assess
the impact of missing records and missing data on our outcomes,
although we have no reason to suspect these were a source of
significant bias in our analysis of clinical risk factors. Some of the
primary VL patients whom we classified as ‘‘primary VL patients
who did not subsequently relapse’’ may have had an untreated or
unrecorded relapse, and some patients who had been previously
treated may have been diagnosed as primary VL if the patient did
not recall their primary episode. These two misclassifications
would lead to under-estimation of risk factors for relapse. The 5
Table 6. Trends in primary and relapse VL in Southern Sudan (1999–2007).
1999 2000 2001 2002 2003 2004 2005 2006 2007 APC
h
Relapse VL
a 4.1% 6.3% 2.8% 2.6% 5.9% 8.5% 4.0% 12.8% 7.6% 11.4% (23.4% to 28.5%)
SSG
b 99.5% 100.0% 99.9% 52.3% 9.6% 31.6% 8.2% 6.7% 0.0% -
SSG/PM
b 0.5% 0.0% 0.1% 47.7% 90.4% 68.4% 91.8% 93.3% 100.0% -
Deaths
c 13.5% 10.0% 7.4% 4.4% 5.6% 3.6% 4.2% 2.9% 2.4% 18.1% (222.5% to 213.4%)
Mean time-to-presentation
of VL relapse patients
(months)
d
3.0 3.3 2.2 2.7 1.8 2.1 1.8 2.4 1.6 26.7% (211.3% to 21.8%)
Mean time-to-presentation
of primary VL patients
(months)
e
2.8 2.4 2.2 1.8 1.6 1.7 1.7 1.9 1.2 27.7% (23.8% to 211.6%)
Hackett Grade $3
f 34.4% 32.5% 25.3% 18.0% 20.0% 22.6% 16.4% 15.0% 16.0% 29.6% (213.5% to 25.5%)
Interval between primary
and relapse VL (days)
g
median 111 86 109 104 101 77 78 78 48 -
(range) (33–198) (24–183) (23–250) (34–623) (19–1358) (27–145) (45–310) (22–240) (48)
patients n=13 n=4 n=18 n=40 n=51 n=13 n=19 n=7 n=1
afrom MSF summary statistics (expressed as proportion of patients treated for primary VL, N=11,319).
bfrom MSF treatment records (proportion of primary VL patients receiving this treatment, N=8,521).
cfrom MSF summary statistics (expressed as proportion of all patients treated, N=12,924).
dfrom MSF treatment records (duration of illness self-reported by VL relapse patients, N=589).
efrom MSF treatment records (duration of illness self-reported by primary VL patients, N=7,841).
ffrom MSF treatment records (spleen size measured in primary VL patients, N=8,494).
gfrom MSF treatment records (interval between discharge and re-admission, N=166).
hAnnual Percentage Change (95% confidence interval) estimated from join-point regression.
doi:10.1371/journal.pntd.0000705.t006
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have been treatment failures, rather than relapses. Through our
sensitivity analysis we attempted to adjust for those patients with
no palpable spleen, who were possibly falsely diagnosed as VL
patients (hence at zero risk of relapse). However, in a setting with
high prevalence of other endemic diseases which cause spleno-
megaly (malaria, typhoid, schistosomiasis, brucellosis, and liver
cirrhosis), some patients with splenomegaly may also not have had
primary VL. We could not conduct a further sensitivity analysis,
based on the actual diagnostic method for each patient
(parasitological, immunological, clinical), because this could not
be deduced from the available data. We noted that relapse VL
patients for whom we could not identify a previous treatment
record had less severe splenomegaly on re-admission than relapse
VL patients whose previous treatment data were used in our
analysis. However, spleen size on admission for relapse VL was not
correlated with spleen size at end of treatment for primary VL,
hence this difference would not have led to an over-estimate of the
association between splenomegaly at end of treatment for primary
VL and subsequent relapse.
Our finding that SSG/PM is associated with increased risk of
relapse is likely to be confounded by improvements in access to
treatment which coincided with the introduction of this shorter
combination drug regimen, and may reflect better survival rates
compared with SSG monotherapy. We await a definitive answer from
a randomised controlled trial of SSG/PM vs SSG currently underway
in East Africa. Meanwhile, our finding that splenomegaly is associated
with increased risk of VL relapse could contribute to revised guidelines
for clinical assessment of VL patients prior to discharge.
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